Mesh Suture Closure for Contaminated Midline Incisional Hernia Repairs: A **Multispecialty Early Outcomes Study**



Megan M Perez MD • Gregory A Dumanian MD • Michael Shapiro MD • Northwestern University, Feinberg School of Medicine. Department of Surgery

INTRODUCTION

Midline incisional hernia repairs in contaminated and clean-contaminated fields pose a significant clinical challenge due to elevated risks of recurrence and surgical site infection (SSI). While permanent planar mesh reinforcement has demonstrated reduced recurrence rates, its use in contaminated settings remains limited by concerns over infection and the technical demands of implantation.

Mesh suture is a novel suture device (Fig 1) that integrates the ease of primary suture repair with the biomechanical advantages of mesh. Its large-pore, braided design aims to distribute tension across the suture-tissue interface, potentially improving outcomes while minimizing the need for extensive dissection and the amount of foreign body load.

Fig 1 Mesh Suture

AIMS/HYPOTHESIS

It was hypothesized that mesh suture could provide improved early mechanical support and complication rates comparable to conventional suture-only and planar mesh-based repairs, as reported in the literature.

METHODS

A retrospective cohort study was conducted of 51 patients undergoing contaminated (CDC III) or cleancontaminated (CDC II) midline, incisional hernia repair with mesh suture between Jan 2023-Jul 2024 across an integrated academic health system. Cases involving planar mesh were excluded. Outcomes included 90-day SSI, surgical site occurrence (SSO), reoperation, readmission, and hernia recurrence. Recurrence-free survival was analyzed using Kaplan-Meier methods, truncated at 18 months.





Fig 2 (a) defect after completion of ostomy and fistula takedown and hernia sac excision, fascial edges were Table 3. Primary and secondary outcomes circumferentially cleared to healthy tissue to optimize approximation, (b) mesh suture closure of defect in a continuous running fashion, using full-thickness, 1 cm through-and-through bites of the anterior abdominal wall with 8 mm travel between bites, (c) immediately postoperative, the incision on the right was used for the right anterior components separation, the ostomy site on the left was used for the left components separation and was then closed transversely.

Bowel resection22 (43.1)Ostomy reversal3 (5.9)Gynecologic procedure4 (7.8)Urologic procedure4 (7.8)Creation of stoma/revision4 (7.8)Enterotomy1 (2.0)Cholecystectomy2 (3.9)Fistula5 (9.8)Lysis of adhesions6 (11.7)Table 2. Operative detailsN = 51 (%)Length of inpatient stay (days) (mean, SD)7.7±6.0Stoma present19 (37.3)Operative time (minutes)328.3±172.6Pre-operative abdominal wall Botox6 (11.8)Anterior components separation13 (25.5)Mesh suture for second indication13 (25.5)Mesh suture for second indication8 (15.7)Parastomal hernia repair4 (7.8)	Table 1. Sources of Contamination					
Gynecologic procedure4 (7.8)Urologic procedure4 (7.8)Creation of stoma/revision4 (7.8)Enterotomy1 (2.0)Cholecystectomy2 (3.9)Fistula5 (9.8)Lysis of adhesions6 (11.7)Table 2. Operative detailsN = 51 (%)Length of inpatient stay (days) (mean, SD)7.7±6.0Stoma present19 (37.3)Operative time (minutes)328.3±172.6Pre-operative abdominal wall Botox6 (11.8)Anterior components separation13 (25.5)Mesh suture for second indication8 (15.7)	Bowel resection	22 (43.1)				
Urologic procedure4 (7.8)Creation of stoma/revision4 (7.8)Enterotomy1 (2.0)Cholecystectomy2 (3.9)Fistula5 (9.8)Lysis of adhesions6 (11.7)Table 2. Operative detailsN = 51 (%)Length of inpatient stay (days) (mean, SD)7.7±6.0Stoma present19 (37.3)Operative time (minutes)328.3±172.6Pre-operative abdominal wall Botox6 (11.8)Anterior components separation13 (25.5)Mesh suture for second indication8 (15.7)	Ostomy reversal	3 (5.9)				
Creation of stoma/revision4 (7.8)Enterotomy1 (2.0)Cholecystectomy2 (3.9)Fistula5 (9.8)Lysis of adhesions6 (11.7)Table 2. Operative detailsN = 51 (%)Length of inpatient stay (days) (mean, SD)7.7±6.0Stoma present19 (37.3)Operative time (minutes)328.3±172.6Pre-operative abdominal wall Botox6 (11.8)Anterior components separation13 (25.5)Mesh suture for second indication8 (15.7)	Gynecologic procedure	4 (7.8)				
Enterotomy1 (2.0)Cholecystectomy2 (3.9)Fistula5 (9.8)Lysis of adhesions6 (11.7)Table 2. Operative detailsTable 2. Operative detailsN = 51 (%)Length of inpatient stay (days) (mean, SD) 7.7 ± 6.0 Stoma present19 (37.3)Operative time (minutes) 328.3 ± 172.6 Pre-operative abdominal wall Botox6 (11.8)Anterior components separation13 (25.5)Mesh suture for second indication8 (15.7)	Urologic procedure	4 (7.8)				
Cholecystectomy2 (3.9)Fistula5 (9.8)Lysis of adhesions6 (11.7)Table 2. Operative detailsN = 51 (%)Length of inpatient stay (days) (mean, SD)7.7±6.0Stoma present19 (37.3)Operative time (minutes)328.3±172.6Pre-operative abdominal wall Botox6 (11.8)Anterior components separation13 (25.5)Mesh suture for second indication8 (15.7)	Creation of stoma/revision	4 (7.8)				
Fistula5 (9.8)Lysis of adhesions6 (11.7)Table 2. Operative detailsTable 2. Operative detailsN = 51 (%)Length of inpatient stay (days) (mean, SD)7.7±6.0Stoma present19 (37.3)Operative time (minutes)328.3±172.6Pre-operative abdominal wall Botox6 (11.8)Anterior components separation13 (25.5)Mesh suture for second indication8 (15.7)	Enterotomy	• •				
Lysis of adhesions6 (11.7)Table 2. Operative detailsN = 51 (%)Length of inpatient stay (days) (mean, SD)7.7±6.0Stoma present19 (37.3)Operative time (minutes)328.3±172.6Pre-operative abdominal wall Botox6 (11.8)Anterior components separation13 (25.5)Mesh suture for second indication328.15.7)	Cholecystectomy	2 (3.9)				
Table 2. Operative detailsN = 51 (%)Length of inpatient stay (days) (mean, SD)Stoma present19 (37.3)Operative time (minutes)328.3±172.6Pre-operative abdominal wall BotoxAnterior components separation13 (25.5)Mesh suture for second indicationOstomy site fascial closure8 (15.7)		. ,				
N = 51 (%)Length of inpatient stay (days) (mean, SD)7.7±6.0Stoma present19 (37.3)Operative time (minutes)328.3±172.6Pre-operative abdominal wall Botox6 (11.8)Anterior components separation13 (25.5)Mesh suture for second indication13 (25.7)	Lysis of adhesions	6 (11.7)				
N = 51 (%)Length of inpatient stay (days) (mean, SD)7.7±6.0Stoma present19 (37.3)Operative time (minutes)328.3±172.6Pre-operative abdominal wall Botox6 (11.8)Anterior components separation13 (25.5)Mesh suture for second indication13 (25.7)	Table 2 Operative details					
Length of inpatient stay (days) (mean, SD)7.7±6.0Stoma present19 (37.3)Operative time (minutes)328.3±172.6Pre-operative abdominal wall Botox6 (11.8)Anterior components separation13 (25.5)Mesh suture for second indication Ostomy site fascial closure8 (15.7)		N = 51 (06)				
Stoma present19 (37.3)Operative time (minutes)328.3±172.6Pre-operative abdominal wall Botox6 (11.8)Anterior components separation13 (25.5)Mesh suture for second indication13 (25.7)						
Operative time (minutes)328.3±172.6Pre-operative abdominal wall Botox6 (11.8)Anterior components separation13 (25.5)Mesh suture for second indication9 (15.7)		19 (37.3)				
Botox6 (11.8)Anterior components separation13 (25.5)Mesh suture for second indication13 (25.7)	-					
Mesh suture for second indication Ostomy site fascial closure 8 (15.7)		6 (11.8)				
indication Ostomy site fascial closure 8 (15.7)	Anterior components separation	13 (25.5)				
Parastomal hernia repair 4 (7.8)	Ostomy site fascial closure	8 (15.7)				
	Parastomal hernia repair	4 (7.8)				

RESULTS



Outcomes are summarized in Table 2. Major complications (SSI, SSO, or reoperation within 90 days) occurred in 21.6% of patients. Stoma presence at the time of hernia repair was significantly associated with complications (p = 0.041).

following mesh suture repair	
	N = 51 (%)
SSI	
Superficial infection	2 (3.9)
Deep infection	2 (3.9)
Organ space infection	4 (7.8)
SSI 0-90 days	8 (15.7)
SSO	
SSI	8 (15.7)
Seroma	4 (7.8)
Hematoma	2 (3.9)
Soft tissue breakdown	1 (2.0)
Fascial dehiscence	1 (2.0)
Cellulitis	0 (0)
Suture granuloma	0 (0)
Chronic draining sinus	0 (0)
Enterocutaneous fistula	1 (2.0)
SSO 0-90 days	12 (23.5)
SSO requiring procedural ntervention	7 (13.7)
leadmissions related to bdominal repair	3 (5.8)
Reoperations related to abdominal repair	5 (9.8)
Death 1-year	3 (5.9)
Hernia recurrence	4 (8.2)
ength of time hernia	
recurrence (mo.)	12.9±7.3
(mean±SD)	




Figure 2 Kaplan-Meier curve demonstrating recurrence-free survival truncated at 18 months. Three hernia recurrences occurred during the truncated follow-up period. An additional recurrence that occurred after 18 months is not shown on this curve but is included in the overall event count. Vertical ticks represent censored observations (patients with no recurrence by last follow-up). Mean length of time to recurrence 12.9 months (±7.3).

CONCLUSION

Mesh suture closure appears feasible for midline hernia repair in contaminated and cleancontaminated settings. In this series, 90-day SSI (15.7%) and SSO (23.5%) rates were within reported ranges for biologic, biosynthetic, and synthetic mesh (SSI 15-24%, SSO 25-48%) [1-4]. No chronic infections occurred.

Mesh suture has a lower foreign material burden and is easily removed when needed. The recurrence rate (8.2%) in this cohort is favorable compared to published real-world rates (23-40%) for planar mesh, though further prospective studies are needed to confirm long-term outcomes.

(1) Warren J et al. Safety and Efficacy of Synthetic Mesh for Ventral Hernia Repair in a Contaminated Field. J Am Coll Surg. 2020;230(4):405-413. doi:10.1016/j.jamcollsurg.2019.12.008; (2) Rosen MJ et al. Multicenter, Prospective, Longitudinal Study of the Recurrence, Surgical Site Infection, and Quality of Life After Contaminated Ventral Hernia Repair Using Biosynthetic Absorbable Mesh: The COBRA Study. Ann Surg. 2017;265(1):205-211 doi:10.1097/SLA.000000000001601; (3) Rosen MJ et al. Biologic vs Synthetic Mesh for Single-stage Repair of Contaminated Ventral Hernias: A Randomized Clinical Trial. JAMA Surg. 2022;157(4):293-301. doi:10.1001/jamasurg.2021.6902; (4) Layer T et al. Incisional hernia repair with a slowly absorbable P4HB mesh: what happens after the mesh disappears? A retrospective longitudinal clinical study. Hernia. 2023;27(2):387-394. doi:10.1007/s10029-022-02616-8; (5) Rodriguez-Quintero JH, et al. Permanent vs Absorbable Mesh for Ventral Hernia Repair in Contaminated Fields: Multicenter Propensity-Matched Analysis of 1-Year Outcomes Using the Abdominal Core Health Quality Collaborative Database. Journal of the American College of Surgeons. 2023;236(2):374. doi:10.1097/XCS.000000000000433



·····	+=++	\$	urvival Function Censored
10	15	20	
Time (0-18 months)			